Publikationen 2011

  1. Alford KA, Reinhardt K, Garnett C, Norton A, Böhmer K, von Neuhoff C, Kolenova A, Marchi E, Klusmann JH, Roberts I, Hasle H, Reinhardt D, Vyas P: Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 2011;118:2222-2238. http://www.ncbi.nlm.nih.gov/pubmed/21715302
  2. Balgobind BV, van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, Arentsen-Peters ST, van Wering ER, Kaspers GJ, Cloos J, de Bont ES, Cayuela JM, Baruchel A, Meyer C, Marschalek R, Trka J, Stary J, Beverloo HB, Pieters R, Zwaan CM, den Boer ML: Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 2011;96:221-230. http://www.ncbi.nlm.nih.gov/pubmed/20971820
  3. Balgobind BV, Hollink IH, Arentsen-Peters ST, Zimmermann M, Harbott J, Beverloo HB, von Bergh AR, Cloos J, Kaspers GJ, de H, V, Zemanova Z, Stary J, Cayuela JM, Baruchel A, Creutzig U, Reinhardt D, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM: Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 2011;96:1478-1487. http://www.ncbi.nlm.nih.gov/pubmed/21791472
  4. Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, Danen-van Oorschot AA, de H, V, Reinhardt D, Klusmann JH, Zimmermann M, Devidas M, Carroll AJ, Basso G, Pession A, Hasle H, Pieters R, Rabin KR, Izraeli S, Zwaan CM: Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 2011;25:1365-1368. http://www.ncbi.nlm.nih.gov/pubmed/21537335
  5. Coenen EA, Raimondi SC, Harbott J, Zimmermann M, Alonzo TA, Auvrignon A, Beverloo HB, Chang M, Creutzig U, Dworzak MN, Forestier E, Gibson B, Hasle H, Harrison CJ, Heerema NA, Kaspers GJ, Leszl A, Litvinko N, Lo NL, Morimoto A, Perot C, Reinhardt D, Rubnitz JE, Smith FO, Stary J, Stasevich I, Strehl S, Taga T, Tomizawa D, Webb D, Zemanova Z, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM: Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood 2011;117:7102-7111. http://www.ncbi.nlm.nih.gov/pubmed/21551233
  6. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, von Neuhoff C, Sander A, von Stackelberg A, Schmid I, Stary J, Steinbach D, Vormoor J, Reinhardt D: Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2011; Epub ahead of print. http://www.ncbi.nlm.nih.gov/pubmed/21968880
  7. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, von Neuhoff C, Sander A, Schrauder A, Teigler-Schlegel A, Stary J, Corbacioglu S, Reinhardt D: Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011;118:5409-5415. http://www.ncbi.nlm.nih.gov/pubmed/21948298

  8. Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Fleischhack G, von Neuhoff C, Sander A, Schrauder A, von Stackelberg A, Ritter J, Stary J, Reinhardt D: CNS irradiation in pediatric acute myleoid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer 2011;57:986-992. http://www.ncbi.nlm.nih.gov/pubmed/21480469
  9. Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, Zwaan CM, de H, V, Creutzig U, Klusmann JH, Krauter J, Heuser M, Ganser A, Reinhardt D, Thiede C: Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia 2011;25:1704-1710. http://www.ncbi.nlm.nih.gov/pubmed/21647152
  10. Dan L, Klimenkova O, Klimiankou M, Klusmann JH, van den Heuvel-Eibrink MM, Reinhardt D, Welte K, Skokowa J: The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2011; Epub ahead of print. http://www.ncbi.nlm.nih.gov/pubmed/22207684
  11. Danen-van Oorschot AA, Kuipers JE, Arentsen-Peters S, Schotte D, de H, V, Trka J, Baruchel A, Reinhardt D, Pieters R, Michel ZC, van den Heuvel-Eibrink MM: Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Pediatr Blood Cancer 2011; Epub ahead of print. http://www.ncbi.nlm.nih.gov/pubmed/21818844
  12. Gobel U, Creutzig U, Klingebiel T, Kaatsch P, Niehues T, Korholz D: [Adolescents with cancer - administrative, clinical and scientific implications]. Klin Padiatr 2011;223:311-314. http://www.ncbi.nlm.nih.gov/pubmed/22052629
  13. Hartmann C, Weinel P, Schmid H, Grigull L, Sander A, Linderkamp C, Welte K, Reinhardt D: Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol 2011;33:344-349. http://www.ncbi.nlm.nih.gov/pubmed/21572345
  14. Hollink IH, Feng Q, Danen-van Oorschot AA, Arentsen-Peters ST, Verboon LJ, Zhang P, de H, V, Reinhardt D, Creutzig U, Trka J, Pieters R, van den Heuvel-Eibrink MM, Wang J, Zwaan CM: Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia 2011; Epub ahead of print. http://www.ncbi.nlm.nih.gov/pubmed/21836609
  15. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Zimmermann M, Peeters JK, Valk PJ, Balgobind BV, Sonneveld E, Kaspers GJ, de Bont ES, Trka J, Baruchel A, Creutzig U, Pieters R, Reinhardt D, Zwaan CM: Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica 2011;96:384-392. http://www.ncbi.nlm.nih.gov/pubmed/21134981
  16. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratcorona M, Abbas S, Kuipers JE, van Galen JF, Beverloo HB, Sonneveld E, Kaspers GJ, Trka J, Baruchel A, Zimmermann M, Creutzig U, Reinhardt D, Pieters R, Valk PJ, Zwaan CM: NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood 2011;118:3645-3656. http://www.ncbi.nlm.nih.gov/pubmed/21813447
  17. Kuipers JE, Coenen EA, Balgobind BV, Stary J, Baruchel A, de H, V, de Bont ES, Reinhardt D, Kaspers GJ, Cloos J, Danen-van Oorschot AA, den Boer ML, Marschalek R, Meyer C, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM: High IGSF4 expression in pediatric M5 acute myeloid leukemia with t(9;11)(p22;q23). Blood 2011;117:928-935. http://www.ncbi.nlm.nih.gov/pubmed/21045196
  18. Malaise M, Neumeier M, Botteron C, Dohner K, Reinhardt D, Schlegelberger B, Gohring G, Gruhn B, Debatin KM, Corbacioglu S: Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice. Leukemia 2011;Epub ahead of print. http://www.ncbi.nlm.nih.gov/pubmed/21647161
  19. Pritchard-Jones K, Lewison G, Camporesi S, Vassal G, Ladenstein R, Benoit Y, Predojevic J, Sterba J, Stary J, Eckschlager T, Schroeder H, Doz F, Creutzig U, Klingebiel T, Kosmidis H, Garami M, Pieters R, O'Meara A, Dini G, Riccardi R, Rascon J, Rageliene L, Calvagna V, Czauderna P, Kowalczyk J, Gil-da-Costa M, Norton L, Pereira F, Janic D, Puskacova J, Jazbec J, Canete A, Hjorth L, Ljungman G, Kutluk T, Morland B, Stevens M, Walker D, Sullivan R: The state of research into children with cancer across Europe: new policies for a new decade. Ecancermedicalscience 2011;5:210-279. http://www.ncbi.nlm.nih.gov/pubmed/22276053
  20. Steinbach D, Wilhelm B, Kiermaier HR, Creutzig U, Schrappe M, Zimmermann M, Debatin KM, Gruhn B, von Stackelberg A, Jurgens H, Strahm B, Reinhardt D, Moricke A: Long term survival in children with acute leukaemia and complications requiring mechanical ventilation. Arch Dis Child 2011;96:1026-1032. http://www.ncbi.nlm.nih.gov/pubmed/21719441
  21. Thol F, Heuser M, Damm F, Klusmann JH, Reinhardt K, Reinhardt D: DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica 2011;96:1238-1240. http://www.ncbi.nlm.nih.gov/pubmed/21685466
Suchen
Benutzeranmeldung